Abiomed Inc. (NASDAQ:ABMD) CEO Michael R. Minogue sold 58,710 shares of the stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $127.00, for a total value of $7,456,170.00. Following the transaction, the chief executive officer now owns 215,782 shares of the company’s stock, valued at $27,404,314. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Shares of Abiomed Inc. (NASDAQ:ABMD) opened at 126.37 on Friday. The company has a market capitalization of $5.41 billion, a PE ratio of 134.44 and a beta of 0.89. The firm has a 50-day moving average price of $121.00 and a 200-day moving average price of $106.20. Abiomed Inc. has a 1-year low of $67.81 and a 1-year high of $127.86.
Abiomed (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.06. Abiomed had a return on equity of 11.86% and a net margin of 11.75%. The business had revenue of $103 million for the quarter, compared to the consensus estimate of $97.23 million. During the same period last year, the business earned $0.20 EPS. The firm’s revenue was up 40.3% compared to the same quarter last year. Equities analysts anticipate that Abiomed Inc. will post $1.17 earnings per share for the current year.
Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Abiomed from a “hold” rating to a “buy” rating and set a $138.00 price objective on the stock in a research note on Friday, September 16th. Jefferies Group restated a “buy” rating and set a $125.00 price objective on shares of Abiomed in a research note on Friday, June 10th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Abiomed currently has a consensus rating of “Buy” and a consensus target price of $115.59.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Cypress Capital Management LLC WY acquired a new position in shares of Abiomed during the second quarter valued at approximately $106,000. Bessemer Group Inc. increased its position in shares of Abiomed by 94.3% in the first quarter. Bessemer Group Inc. now owns 1,226 shares of the company’s stock valued at $116,000 after buying an additional 595 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Abiomed by 28.8% in the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,243 shares of the company’s stock valued at $136,000 after buying an additional 278 shares in the last quarter. Advisor Group Inc. acquired a new position in shares of Abiomed during the second quarter valued at approximately $204,000. Finally, World Asset Management Inc acquired a new position in shares of Abiomed during the second quarter valued at approximately $209,000. 93.65% of the stock is currently owned by institutional investors.
Abiomed Company Profile
Receive News & Ratings for Abiomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.